For the quarter ending 2025-09-30, RLYB had $22,677K increase in cash & cash equivalents over the period.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | 16,016 | -19,142 |
| Depreciation and amortization | 35 | 54 |
| Net accretion of discounts/premiums on debt securities | -113 | -363 |
| Share-based compensation | 1,047 | 3,493 |
| Equity method investment, realized gain on disposal | 22,350 | - |
| Loss on investment in joint venture | 0 | -874 |
| Prepaid expenses, operating lease right-of-use assets and other current assets | 773 | 2,085 |
| Accounts payable | 150 | -159 |
| Accrued expenses and operating lease liabilities | -350 | -832 |
| Deferred revenue | -212 | -424 |
| Net cash used in operating activities | -6,550 | -18,584 |
| Purchases of marketable securities | 738 | 9,884 |
| Proceeds from maturities of marketable securities | 9,965 | 25,500 |
| Proceeds from sale of common stock received from sale of joint venture | 20,000 | - |
| Investment in joint venture | 0 | 1,500 |
| Net cash provided by investing activities | 29,227 | 14,116 |
| Proceeds from the issuance of common stock from a securities purchase agreement | 0 | 0 |
| Proceeds from the issuance of common stock under the stock purchase plan | 0 | 10 |
| Payments of offering costs | 0 | 0 |
| Net cash provided by financing activities | 0 | 10 |
| Net increase in cash and cash equivalents | 22,677 | -4,458 |
| Cash and cash equivalents at beginning of period | 13,903 | - |
| Cash and cash equivalents at end of period | 32,122 | - |
Rallybio Corp (RLYB)
Rallybio Corp (RLYB)